Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.

Abstract excerpt

Although recent success in identifying direct inhibitors of mutant Ras has begun to challenge the perception that Ras is "undruggable," the successful transition of these hits to the clinic remains uncertain. Therefore, current efforts to develop anti-Ras inhibitors are focused on indirect approa...

Topics

• Animals
• Antineoplastic Agents
• Enzyme Inhibitors
• Extracellular Signal-Regulated MAP Kinases
• Humans
• Mitogen-Activated Protein Kinases
• Mutation
• Neoplasms
• ras Proteins